The voice of the renal industry to the NHS, government, patients and the clinical community.
To be a vehicle for the two-way communication of developments and innovations between industry and the NHS.
To develop an environment for true collaborative working with all stakeholders.
To ensure fair market access to all developments and innovations for the benefit of patients and the renal community.
To deliver industry consensus to all stakeholders within the renal community for the benefit of patients.
The Association of Renal Industries (ARI) is the voice of the renal industry to the NHS, government, patients and the clinical community.
Our membership is made up of renal based companies comprising the speciality areas of:
devices, pharmaceuticals, service, nutrition, consulting, imaging and venture capital.
To influence renal policy, at all levels for the benefit of all stakeholders.
To identify current and future issues which may affect the renal industry and respond proactively.
The ARI is a key point of contact with the Department of Health, British Renal Society (BRS) and the Renal Association (RA).
We have close collaboration with the National Kidney Federation (NKF), Kidney Research UK, the Government / MPs, and other professional bodies / groups.
We are a registered stakeholder in the National Institute for Health and Care Excellence (NICE) guidance.
We have active representation on the BRS council and the Association of Renal Technicians (ART).
Member companies have a single vote, irrespective of UK renal financial turnover.
Currently the ARI has approximately 20 member companies drawn from the dialysis supplies and service companies, pharmaceutical, biotechnology, water treatment and specialist renal IT companies. The ARI represents the interests of both very large and small companies on any issues impacting on the renal industry.
Opportunity to influence renal policy for the benefit of patients, industry and the renal community.
Provision of training and development in line with market legislation.
Monthly communication with up-to-date information on renal issues affecting industry and other stakeholders.
Direct contact opportunities with key opinion leaders.